Raymond James Financial reissued their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research note published on Tuesday morning.

A number of other research firms have also issued reports on RARE. Barclays increased their target price on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an equal weight rating in a report on Tuesday. Canaccord Genuity set a $80.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a buy rating in a research note on Tuesday. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research report on Wednesday, November 8th. J P Morgan Chase & Co set a $76.00 target price on shares of Ultragenyx Pharmaceutical and gave the stock a buy rating in a research report on Wednesday, August 23rd. Finally, Morgan Stanley reissued an equal weight rating and set a $69.00 target price (down from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Ten research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $72.40.

Shares of Ultragenyx Pharmaceutical (NASDAQ RARE) traded down $1.80 during trading hours on Tuesday, hitting $49.96. The stock had a trading volume of 1,220,000 shares, compared to its average volume of 438,033. Ultragenyx Pharmaceutical has a one year low of $44.02 and a one year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, meeting analysts’ consensus estimates of ($1.87). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. Ultragenyx Pharmaceutical’s revenue was up 81.8% on a year-over-year basis. During the same quarter last year, the company posted ($1.64) EPS. sell-side analysts forecast that Ultragenyx Pharmaceutical will post -7.26 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its position in Ultragenyx Pharmaceutical by 7.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 248 shares in the last quarter. Tocqueville Asset Management L.P. lifted its position in Ultragenyx Pharmaceutical by 8.0% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 250 shares in the last quarter. Aperio Group LLC lifted its position in Ultragenyx Pharmaceutical by 8.4% in the 2nd quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock valued at $239,000 after acquiring an additional 299 shares in the last quarter. Amalgamated Bank lifted its position in Ultragenyx Pharmaceutical by 7.6% in the 2nd quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock valued at $309,000 after acquiring an additional 352 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its position in Ultragenyx Pharmaceutical by 12.0% in the 2nd quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 365 shares in the last quarter. 94.13% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical (RARE) Receives “Buy” Rating from Raymond James Financial” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/06/ultragenyx-pharmaceutical-rare-receives-buy-rating-from-raymond-james-financial.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.